For The Better

Opendoor’s $9 billion war chest shows that it means business about taking over real estate.

Open enrollment is coming. Don’t fall victim to these blunders.

The drugmaker’d recent stock struggles present a terrific buying opportunity.

Here’s how this recent IPO differentiates itself.

These three blue-chip stocks are each featured as a top 20 holding of Warren Buffett’s Berkshire Hathaway.

These are two companies you can buy and hold forever.

Christmas might be in trouble. These companies aren’t.

Dogecoin may be trendier, but Ethereum is more likely to pay off down the road.

Investing in the stock market in October doesn’t have to be complicated.

These are two no-brainer stocks to invest in this month.

They’re trading even lower than when they first went public.

Five9 isn’t the only player in cloud-based business contact centers, so Zoom could still go shopping.

Many seniors can’t afford a massive hit to their benefits. Can you?

AI is quickly becoming more useful in our world, and these two companies are perfectly positioned to benefit from it.

You might hate its chumbox ads, but the business is growing like a weed.

Cancer drug Libtayo could receive FDA approval for its fourth indication in January.

An analyst’s downgrade following downbeat comments from management has pushed the robotic surgery company’s stock down to an attractive price.

Here are some guidelines to help you evaluate your financial position.

Worried about losing money on your investments? You’re not alone. Here’s how to calm those nerves and be successful.

Get (and keep) as much as you are entitled to.